(MENAFNEditorial)
Dr. Aleksandr Itkin a dermatologist and President of GeneImpact Inc. has made it a personal mission to prevent skin cancer among children having been diagnosed with melanoma himself at the age of 28.
Skin cancer particularly melanoma is a growing health concern.
For over a span of 4 decades since the 1970s there has been an 800 percent increase in the incidence of melanoma among young American women and 400 percent of young men. Additionally approximately 1 person dies of melanoma every 57 minutes. However not everything is bad news. With recent advances in the understanding of disease causation and treatment technology the melanoma survival rates are now greater than 92 percent compared to 49 percent in the 1950s. However melanoma treatment is not cheap. Melanoma treatment in the United States accounts for $3.3 billion every year with an additional $2.85 billion in work productivity losses while the total expenses for treatment of all types of skin cancer stand at $8.1 billion annually. It is clear that melanoma can be treated but at a hefty price tag.
There should be an effective way of preventing melanoma and non-melanoma skin cancer right at the very start. This will significantly reduce the costs of treating skin cancers and melanoma as well as the financial costs of work productivity losses.
Around 86 percent of all melanoma cases and almost 100% of non-melanoma skin cancers are attributed to prolonged exposure to the sun's ultraviolet radiation. And as individuals continually get exposed to the sun the growing percentage of UV exposure gradually increases over a span of 80 years. In the management of melanoma and non-melanoma skin cancer prevention must therefore be geared towards the under-18 age bracket of the population where they are expected to account for an average accumulated UV exposure of 22.73 percent.
Dr. Aleksandr Itkin a dermatologist and President of GeneImpact Inc. has made it a personal mission to prevent skin cancer among children having been diagnosed with melanoma himself at the age of 28. GeneImpact Inc. is partnering up with Sunscreen Mist a company who's patented sunscreen application system is considered convenient and effective in addition to being simple to use. GeneImpact Inc. has an exclusive distribution right for California Arizona and Nevada K-12 schools but that may expand to all the US Southern belt states. For educational institutions the Sunscreen Mist system is inexpensive low maintenance highly customizable and very durable to make a significant investment in safeguarding the health of all pupils and students against melanoma and non-melanoma skin cancers.
Sunscreen Mist system comes with two solutions – the dual spray station and the booth system. Both systems contain FDA-approved sunscreen lotion mist that is rated at SPF 50 hypoallergenic water resistant and fragrance-free. Additionally the aloe vera and water-based formulation do not carry chemicals like nanoparticles parabens and oxybenzone. The Sunscreen Mist systems can be conveniently operated with a swipe of the student's or the teacher's ID cards and expected to deliver the correct amounts of sunscreen lotion within 5 to 10 seconds. An excellent fixture in dressing rooms stadiums swimming pools football fields and school playgrounds the Sunscreen Mist is a welcome service by institutions to their students and pupils.
Dr. Itkin believes that with GeneImpact Inc. and Sunscreen Mist system combining forces will combat genetic damage to skin in-turn the younger generation will have a greater chance of preventing melanoma in their lifetime. For schools and parents this will be a very significant development in their children's young lives.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.